NomoCan Pharmaceuticals
NomoCan is a biotechnology company developing selective conformational monoclonal antibodies and antibody-drug conjugates (ADCs) that target tumor-restricted protein variants across multiple cancer types. The company is also developing non-invasive liquid biopsy diagnostics intended to identify patients likely to respond to its targeted therapies and to support early detection and patient stratification. Programs are in preclinical development with reported ex vivo activity on patient tumors and efficacy in rodent models.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Lead tumor-selective antibody therapeutic candidate (ADC-enabled)
A preclinical conformational antibody candidate engineered to selectively bind tumor-specific protein variants, developed as a therapeutic antibody and as an antibody-drug conjugate for aggressive cancers, with lead indication in pancreatic cancer.
Antibody-based liquid biopsy diagnostic candidate
A diagnostic assay concept that uses tumor-restricted antibody detection in blood samples to identify and stratify patients for targeted antibody therapy and to support early cancer detection efforts.
first class
Novel biologics that bind exclusively to specific conformational epitopes on proteins in cancer cells, unlocking superior efficacy with a significantly improved safety profile.
First-in-Class Targeted Biologics
Targeted biologics developed for the treatment of some of the most aggressive cancers with unmet medical need.
Non-Invasive Liquid Biopsy Detection
Highly selective diagnostic and prognostic assays leveraging non-invasive liquid biopsy for early detection, patient stratification, and precision-guided treatment strategies.
Lead tumor-selective antibody therapeutic candidate (ADC-enabled)
A preclinical conformational antibody candidate engineered to selectively bind tumor-specific protein variants, developed as a therapeutic antibody and as an antibody-drug conjugate for aggressive cancers, with lead indication in pancreatic cancer.
Antibody-based liquid biopsy diagnostic candidate
A diagnostic assay concept that uses tumor-restricted antibody detection in blood samples to identify and stratify patients for targeted antibody therapy and to support early cancer detection efforts.
first class
Novel biologics that bind exclusively to specific conformational epitopes on proteins in cancer cells, unlocking superior efficacy with a significantly improved safety profile.
First-in-Class Targeted Biologics
Targeted biologics developed for the treatment of some of the most aggressive cancers with unmet medical need.
Non-Invasive Liquid Biopsy Detection
Highly selective diagnostic and prognostic assays leveraging non-invasive liquid biopsy for early detection, patient stratification, and precision-guided treatment strategies.
Services
End-to-end preclinical R&D services for discovery, lead optimization, and efficacy testing of tumor-selective antibodies and ADC candidates.
Development of non-invasive assays intended to detect tumor-restricted antigens in blood for early detection and to guide patient selection for targeted therapy.
End-to-end preclinical R&D services for discovery, lead optimization, and efficacy testing of tumor-selective antibodies and ADC candidates.
Development of non-invasive assays intended to detect tumor-restricted antigens in blood for early detection and to guide patient selection for targeted therapy.
Expertise Areas
- Monoclonal antibody therapeutic development
- Antibody-drug conjugate (ADC) development
- Liquid biopsy and non-invasive diagnostics
- Biomarker discovery and patient stratification
Key Technologies
- Monoclonal antibody engineering
- Antibody-drug conjugate design
- Liquid biopsy assay development
- Ex vivo patient tumor assays